185 related articles for article (PubMed ID: 10829253)
1. Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists.
Mitrovic V; Oehm E; Thormann J; Pitschner H; Hamm C
Herz; 2000 Mar; 25(2):130-42. PubMed ID: 10829253
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.
Mitrovic V; Oehm E; Thormann J; Pitschner H; Haberbosch W
Clin Cardiol; 1998 Jul; 21(7):492-502. PubMed ID: 9669058
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic, antiischemic, and neurohumoral effects of tedisamil and atenolol in patients with coronary artery disease.
Mitrovic V; Miskovic A; Strau M; Thormann J; Pitschner H; Hamm C
Cardiovasc Drugs Ther; 2000 Oct; 14(5):511-21. PubMed ID: 11101199
[TBL] [Abstract][Full Text] [Related]
4. [Effects of the K(+) channel blocker tedisamil on hemodynamics, myocardial ischemia and neurohumoral systems in patients with stable angina pectoris. A comparison with the beta blocker atenolol].
Mitrovic V; Miskovic A; Straub M; Beckmann K; Thormann J; Pitschner H
Z Kardiol; 1999 Oct; 88(10):838-49. PubMed ID: 10552188
[TBL] [Abstract][Full Text] [Related]
5. [The new potassium channel blocker tedisamil and its hemodynamic, anti-ischemic and neurohumoral effect in patients with coronary heart disease].
Mitrovic V; Oehm E; Strasser R; Schlepper M; Pitschner HF
Z Kardiol; 1996 Dec; 85(12):961-72. PubMed ID: 9082675
[TBL] [Abstract][Full Text] [Related]
6. Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris.
Burian M; Piske M; Petkovic D; Mitrovic V
Cardiovasc Drugs Ther; 2004 Jan; 18(1):37-46. PubMed ID: 15115902
[TBL] [Abstract][Full Text] [Related]
7. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs.
Yao Z; Gross GJ
Circulation; 1994 Apr; 89(4):1769-75. PubMed ID: 8149542
[TBL] [Abstract][Full Text] [Related]
8. [Anti-ischemia effects of gallopamil and esmolol in an intra-individual comparison in patients with coronary heart disease].
Mitrovic V; Oehm E; Minge C; Thürmann P; Schlepper M
Z Kardiol; 1994 Jun; 83(6):431-8. PubMed ID: 7915067
[TBL] [Abstract][Full Text] [Related]
9. Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker.
Fox KM; Henderson JR; Kaski JC; Sachse A; Kuester L; Wonnacott S
Heart; 2000 Feb; 83(2):167-71. PubMed ID: 10648489
[TBL] [Abstract][Full Text] [Related]
10. Tedisamil: master switch of nature?
Doggrell SA
Expert Opin Investig Drugs; 2001 Jan; 10(1):129-38. PubMed ID: 11116286
[TBL] [Abstract][Full Text] [Related]
11. Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats.
Rees SA; Tsuchihashi K; Hearse DJ; Curtis MJ
J Cardiovasc Pharmacol; 1993 Sep; 22(3):343-9. PubMed ID: 7504122
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.
Kuhn A; Carlsson J; Miketic S; Tebbe U
Cardiovasc Drugs Ther; 1995 Aug; 9(4):595-600. PubMed ID: 8547210
[TBL] [Abstract][Full Text] [Related]
13. Tedisamil (Solvay).
Flores NA
Curr Opin Investig Drugs; 2001 Jan; 2(1):97-103. PubMed ID: 11527020
[TBL] [Abstract][Full Text] [Related]
14. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs.
Mizumura T; Nithipatikom K; Gross GJ
Circulation; 1995 Sep; 92(5):1236-45. PubMed ID: 7648671
[TBL] [Abstract][Full Text] [Related]
15. Tedisamil in a chronic canine model of atrial flutter.
Fischbach PS; Johnston PV; Friedrichs GS; Lucchesi BR
J Cardiovasc Pharmacol; 1999 Aug; 34(2):212-8. PubMed ID: 10445672
[TBL] [Abstract][Full Text] [Related]
16. Effects of administration of nicorandil or bimakalim prior to and during ischemia or reperfusion on survival rate, ischemia/reperfusion-induced arrhythmias and infarct size in anesthetized rabbits.
Das B; Sarkar C; Karanth KS
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):383-96. PubMed ID: 11692221
[TBL] [Abstract][Full Text] [Related]
17. Tedisamil (KC 8857) is a new specific bradycardic drug: does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease.
Thormann J; Mitrovic V; Riedel H; Neuzner J; Strasser R; Bahavar H; Schlepper M
Am Heart J; 1993 May; 125(5 Pt 1):1233-46. PubMed ID: 8480574
[TBL] [Abstract][Full Text] [Related]
18. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers.
Démolis JL; Martel C; Funck-Brentano C; Sachse A; Weimann HJ; Jaillon P
Br J Clin Pharmacol; 1997 Oct; 44(4):403-9. PubMed ID: 9354317
[TBL] [Abstract][Full Text] [Related]
19. Tedisamil: a new novel antiarrhythmic.
Freestone B; Lip GY
Expert Opin Investig Drugs; 2004 Feb; 13(2):151-60. PubMed ID: 14996649
[TBL] [Abstract][Full Text] [Related]
20. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.
Baczkó I; Leprán I; Papp JG
Eur J Pharmacol; 1997 Apr; 324(1):77-83. PubMed ID: 9137916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
